GC Biopharma wins approval for quadrivalent flu vaccine in Egypt

South Korea's GC Biopharma Co. announced on Wednesday that its quadrivalent influenza vaccine "GC Flu Quadrivalent" has received approval from Egyptian health regulatory authorities.

This is the first approval for this product in the African continent. According to the company, Egypt is one of the countries with the largest pharmaceutical markets in Africa.

Based on this approval, the company plans to expand its export markets beyond Southeast Asia and Latin America to Africa and the Middle East, and accelerate its entry into specific private-sector markets in each country.

"Based on our excellent vaccine technology and manufacturing capabilities accumulated over half a century, we will continue to increase our global market share," said Huh Eun-chul, CEO of GC Biopharma.